Page 52 - 2019_09-HaematologicaMondo-web

Y. Saunthararajah et al.
refractory to 5-azacitidine. Leuk
Lymphoma. 2014;55(2):447-449.
114. Tabarroki A, Saunthararajah Y, Visconte V, et al. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk Lymphoma.
2015;56(2):497-499.
115.Saunthararajah Y, Triozzi P, Rini B, et al.
p53-independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol. 2012;39(1):97-108.
116.Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: a plausible model. J Mol Biol. 1965;12:88-118.
117.Eaton WA, Henry ER, Hofrichter J, et al. Evolution of allosteric models for hemoglo- bin. IUBMB Life. 2007;59(8-9):586-599.
118.Hebbel RP, Hedlund BE. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Am J Hematol. 2018;93(3):321-325.
119. Beutler E. The effect of methemoglobin for- mation in sickle cell disease. J Clin Invest. 1961;40:1856-1871.
120.Howard J, Thein SL, Galacteros F, et al. Safety and tolerability of MP4CO: a dose escalation study in stable patients with sick-
le cell disease. Blood. 2013;122(21):2205. 121. Iyamu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J
Haematol. 2002;118(1):337-343.
122.Swift R, Abdulmalik O, Chen QK, et al.
SCD-101: a new anti-sickling drug reduces pain and fatigue and improves red blood cell shape in peripheral blood of patients with sickle cell disease. Blood. 2016;128 (22):121.
123. Howard J, Hemmaway CJ, Telfer P, et al. A phase 1/2 ascending dose study and open- label extension study of voxelotor in patients with sickle cell disease. Blood. 2019;133(17):1865-1875.
124. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019 Jun 14. [Epub ahead of print]
125. Watchmaker JM, Juttukonda MR, Davis LT, et al. Hemodynamic mechanisms underly- ing elevated oxygen extraction fraction (OEF) in moyamoya and sickle cell anemia patients. J Cereb Blood Flow Metab. 2018;38(9):1618-1630.
126. Choudhury NA, DeBaun MR, Ponisio MR, et al. Intracranial vasculopathy and infarct recurrence in children with sickle cell anaemia, silent cerebral infarcts and normal
transcranial Doppler velocities. Br J
Haematol. 2018;183(2):324-326.
127. Ford AL, Ragan DK, Fellah S, et al. Silent
infarcts in sickle cell disease occur in the bor- der zone region and are associated with low cerebral blood flow. Blood. 2018;132(16): 1714-1723.
128. Quinn CT. Silent cerebral infarction: supply and demand. Blood. 2018;132(16):1632- 1634.
129. Niihara Y, Miller ST, Kanter J, et al. A Phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226-235.
130. Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits dif- ferentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40(4):342- 355.e1.
131.Anand S, Thomas S, Hyslop T, et al. Transplantation of ex vivo expanded umbil- ical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant. 2017;23(7):1151-1157.
132.Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicoti- namide provides long-term multilineage engraftment. J Clin Invest. 2014;124(7):3121- 3128.
1730
haematologica | 2019; 104(9)